Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVMD Revolution Medicines, Inc.

已收盘 10-12 16:00:00 EDT

193.95

+4.19

+2.21%

盘后193.95

+0.000.00%

19:35 EDT

最高194.26	最低184.76	成交量166.74万
今开187.79	昨收189.76	日振幅5.01%
总市值415.71亿	流通市值358.81亿	总股本2.14亿
成交额3.20亿	换手率0.90%	流通股本1.85亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":193.95,"timestamp":1791835200000,"preClose":189.76,"halted":0,"volume":1667435,"hourTrading":{"tag":"盘后","latestPrice":193.95,"preClose":193.95,"latestTime":"19:35 EDT","volume":9909,"amount":1921264.1312,"timestamp":1791848106064,"change":0,"changeRate":0,"amplitude":0.019696},"delay":0,"changeRate":0.02208052276559864,"floatShares":185000000,"shares":214336418,"eps":-8.921187,"marketStatus":"已收盘","change":4.19,"latestTime":"10-12 16:00:00 EDT","open":187.79,"high":194.26,"low":184.76,"amount":319885982.82025003,"amplitude":0.050063,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.921187,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791878400000},"marketStatusCode":5,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":189.76,"preHourTrading":{"tag":"盘前","latestPrice":187.66,"preClose":189.76,"latestTime":"09:29 EDT","volume":2098,"amount":394166.6803,"timestamp":1791811799999,"change":-2.1,"changeRate":-0.011067,"amplitude":0.021349},"postHourTrading":{"tag":"盘后","latestPrice":193.95,"preClose":193.95,"latestTime":"19:35 EDT","volume":9909,"amount":1921264.1312,"timestamp":1791848106064,"change":0,"changeRate":0,"amplitude":0.019696},"volumeRatio":0.73717,"impliedVol":0.5004,"impliedVolPercentile":0.2151},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"1157993410","title":"异动解读｜Revolution Medicines盘中下跌5.23%，生物科技板块普跌拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1157993410","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157993410?lang=zh_cn&edition=full","pubTime":"2026-10-06 22:13","pubTimestamp":1791295997,"startTime":"0","endTime":"0","summary":"10月6日，Revolution Medicines盘中下跌5.23%，报197.13美元/股，成交额4144.94万美元。该公司所在的生物科技行业中，整体表现疲软，个股中，Vaxcyte下跌11.45%，Moderna下跌6.06%，Natera下跌5.54%，Twist Bioscience下跌4.92%，安进下跌1.08%。Revolution Medicines是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法以抑制RAS成瘾癌症的前沿靶点，拥有先进的基于结构的药物发现能力及针对RAS通路关键信号节点的深层研发管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169773730","title":"异动解读｜Revolution Medicines盘中上涨5.06%，多家投行上调目标价叠加FDA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1169773730","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169773730?lang=zh_cn&edition=full","pubTime":"2026-09-25 23:46","pubTimestamp":1790351218,"startTime":"0","endTime":"0","summary":"9月25日，Revolution Medicines盘中上涨5.06%，报210.03美元/股，成交额1.91亿美元。消息面上，近期多重利好持续发酵。9月15日，公司核心产品Rasonque联合化疗获FDA突破性疗法认定，用于一线转移性胰腺癌治疗，进一步拓宽商业化前景。此前Rasonque已于8月底获FDA批准上市，30天疗程定价39,800美元。RBC预计Rasonque将实现快速放量，估算全年美国销售额约2.49亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Revolution Medicines获突破性疗法，投行集体上调目标价","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144894003","title":"异动解读｜Revolution Medicines盘中上涨5.09%，多家投行上调目标价叠加FDA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1144894003","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144894003?lang=zh_cn&edition=full","pubTime":"2026-09-25 03:37","pubTimestamp":1790278646,"startTime":"0","endTime":"0","summary":"9月25日，Revolution Medicines盘中上涨5.09%，报200.44美元/股，成交额5.38亿美元。消息面上，近期多重利好持续发酵。9月15日，公司核心产品Rasonque联合化疗获FDA突破性疗法认定，用于一线转移性胰腺癌治疗，进一步拓宽商业化前景。Rasonque于8月底获FDA批准上市，30天疗程定价39,800美元，RBC预计该药将实现快速放量，预估全年美国销售额达2.49亿美元。Revolution Medicines成立于2014年，是一家精准肿瘤学公司，专注于开发靶向RAS成瘾癌症的创新疗法，拥有深厚的化学生物学和药物发现能力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"获FDA突破性疗法认定，股价强势上涨","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193246198","title":"异动解读｜Revolution Medicines盘中下跌5.1%，报194.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193246198","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193246198?lang=zh_cn&edition=full","pubTime":"2026-09-17 03:19","pubTimestamp":1789586364,"startTime":"0","endTime":"0","summary":"9月17日，Revolution Medicines盘中下跌5.1%，报194.42美元/股，成交额3.34亿美元。Revolution Medicines所在的生物科技行业中，个股表现分化。行业个股中，Moderna跌0.78%，艾伯维跌0.49%，安进跌0.02%，吉利德科学涨0.66%，Natera跌1.76%。Revolution Medicines是一家临床阶段精准肿瘤学公司，专注于开发靶向RAS成瘾癌症的疗法。其核心产品Rasonque已获FDA批准用于转移性胰腺癌治疗，并于近日获得突破性疗法认定用于一线联合化疗方案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165924054","title":"Revolution Medicines宣布Rasonque™（Daraxonrasib）联合化疗获美国FDA突破性疗法认定，用于一线转移性胰腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165924054","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165924054?lang=zh_cn&edition=full","pubTime":"2026-09-15 04:06","pubTimestamp":1789416374,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc.今日宣布，其研发的创新药物Rasonque与化疗药物联用，已获得美国食品药品监督管理局授予的突破性疗法认定。这一认定针对的适应症为一线治疗转移性胰腺癌。此项突破性疗法认定标志着该联合治疗方案在临床试验中展现出显著的治疗潜力，有望为预后极差的转移性胰腺癌患者带来新的治疗选择。这一进展不仅为Revolution Medicines的研发管线注入了强劲动力，也让医学界对攻克胰腺癌这一顽固性疾病增添了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE0002141913.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BBH","IE00B2B36J28.USD","LU0320765992.SGD","LU0889565916.HKD","PTH","BK4139","IE00BJJMRZ35.SGD","IDNA","IE00BJT1NW94.SGD","RVMD","CANC","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186962882","title":"Revolution Medicines获摩根士丹利首次覆盖，给予“增持”评级，目标价255美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186962882","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186962882?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:10","pubTimestamp":1789035009,"startTime":"0","endTime":"0","summary":"摩根士丹利近日宣布首次覆盖生物制药公司Revolution Medicines, Inc.，并给予其“增持”评级。该机构将目标股价设定为每股255美元。这一举措标志着华尔街主要投行对这家专注于研发创新疗法的企业前景持乐观态度。值得注意的是，摩根士丹利的这一评级和价格目标，为投资者提供了新的参考坐标。此前，市场对Revolution Medicines的关注度持续攀升，尤其在肿瘤治疗领域，其管线布局备受瞩目。此次覆盖报告的出炉，或将在短期内影响该股的市场情绪与交易动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE0009354923.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE0002141913.USD","BK4139","IE00B2B36J28.USD","IE00BJT1NW94.SGD","PTH","IE00BFTCPJ56.SGD","LU0889565916.HKD","CANC","IE00B4R5TH58.HKD","LU0320765992.SGD","IDNA","BBH","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554138","title":"Stifel上调Revolution Medicines目标价至230美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554138","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666554138?lang=zh_cn&edition=full","pubTime":"2026-09-10 11:17","pubTimestamp":1789010271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0009355771.USD","PTH","BBH","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00B2B36J28.USD","RVMD","LU0109394709.USD","IE00B4R5TH58.HKD","UUP","CANC","IE00BJT1NW94.SGD","IDNA","UDN","LU0889565916.HKD","IE0009354923.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106079427","title":"异动解读｜Revolution Medicines盘中下跌5.02%，新药获批利好兑现后遭获利了结","url":"https://stock-news.laohu8.com/highlight/detail?id=1106079427","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106079427?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:31","pubTimestamp":1787927476,"startTime":"0","endTime":"0","summary":"8月28日，Revolution Medicines盘中下跌5.02%，报210.055美元/股，成交额1.04亿美元。消息面上，FDA于8月26日正式批准公司旗下首款RAS靶向口服药Rasonque上市，用于治疗转移性胰腺癌，将患者中位生存期从6.7个月延长至13.2个月。该药年费超47.5万美元，30天疗程批发价39,800美元。然而，公司股价年内累计涨幅已超166%，市场此前已充分预期获批，属典型\"利好兑现\"式回调。此外，当日生物科技板块整体承压，Moderna跌5.72%、BioNTech跌8.15%，行业情绪偏弱亦加剧跌势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"新药获批利好兑现，Revolution Medicines回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061828","title":"美国FDA批准胰腺癌突破性药物 独立药企Revolution Medicines迎里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061828","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662061828?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:15","pubTimestamp":1787912149,"startTime":"0","endTime":"0","summary":"Revolution Medicines历时近十年持续攻关，在500人规模临床试验中获得积极数据，最终获得监管批准。为完成交易，戈德史密斯与Warp Drive最大股东赛诺菲协商，将后者持有的Warp Drive多数股权置换为Revolution Medicines的部分股权，最终达成协议。在正式获批前，美国食品药品管理局已通过同情用药项目允许Revolution Medicines提前约四个月向患者分发药物，截至获批时已有超过2000名患者纳入该项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-28/doc-inipwhrt5845666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IDNA","IE0009355771.USD","BK4585","IE00B2B36J28.USD","BK4588","LABU","BK4139","IE0009354923.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","BBH","IE00BFTCPJ56.SGD","IE0002141913.USD","RVMD","IE00B4R5TH58.HKD","PTH","CANC","IE00BJT1NW94.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722025","title":"杰富瑞：将Revolution Medicines目标价从242美元上调至270美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662722025?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:50","pubTimestamp":1787802605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0002141913.USD","IE00BJJMRZ35.SGD","BBH","IE00BJT1NW94.SGD","LU0109394709.USD","UUP","CANC","IE0009354923.USD","IE00B2B36J28.USD","RVMD","PTH","IE0009355771.USD","LU0889565916.HKD","LU0320765992.SGD","IE00B4R5TH58.HKD","IDNA","BK4139","IE00BFTCPJ56.SGD","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662741140","title":"胰腺癌治疗迎历史性突破！FDA批准RevMed靶向新药，预计2032年销售超90亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662741140","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662741140?lang=zh_cn&edition=full","pubTime":"2026-08-27 03:59","pubTimestamp":1787774360,"startTime":"0","endTime":"0","summary":"$Revolution Medicines$旗下胰腺癌新药daraxonrasib获得$美国食品$药品监督管理局批准上市，成为首款针对该疾病关键分子致病机制的靶向药物，标志着胰腺癌治疗领域多年来最重要的突破之一。该药以商品名Rasonque上市，年标价超47.5万美元。消息公布后，RevMed股价上涨，截至发稿盘中上涨2.5%，今年以来累计涨幅已超过一倍，公司市值突破450亿美元。华尔街分析师预测，该药2032年销售额有望超过90亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/cf00d3e001bd81b11eb9b57bd44b96ab","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cf00d3e001bd81b11eb9b57bd44b96ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3780372","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"胰腺癌治疗迎历史性突破！FDA批准RevMed靶向新药，预计2032年销售超90亿美元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1164882019","title":"Revolution Medicines旗下Rasonque美国正式上市，30天疗程批发采购价39,800美元——电话会议披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1164882019","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164882019?lang=zh_cn&edition=full","pubTime":"2026-08-27 01:57","pubTimestamp":1787767031,"startTime":"0","endTime":"0","summary":"Revolution Medicines公司日前宣布，其研发的Rasonque药物现已在美国市场正式商业化供应。这款产品的批发采购成本定为39,800美元，对应30天的用药剂量。值得注意的是，此次上市定价反映了Rasonque在精准肿瘤治疗领域的差异化价值主张。从商业角度看，这一价格策略也释放出Revolution Medicines对其产品竞争力的强烈信心。分析人士指出，随着Rasonque正式进入流通渠道，相关供应链与市场准入工作已全面启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0109394709.USD","CANC","BBH","BK4139","IDNA","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","PTH","IE00B4R5TH58.HKD","LU0320765992.SGD","IE0009354923.USD","RVMD","IE00BJT1NW94.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156385670","title":"美国FDA批准Revolution Medicines旗下Rasonque™（Daraxonrasib）上市，开创转移性胰腺癌广谱Ras靶向治疗先河","url":"https://stock-news.laohu8.com/highlight/detail?id=1156385670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156385670?lang=zh_cn&edition=full","pubTime":"2026-08-27 01:00","pubTimestamp":1787763644,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了Revolution Medicines研发的Rasonque——这标志着全球首款针对转移性胰腺癌的广谱Ras靶向药物成功问世。此举不仅为晚期胰腺癌患者带来了全新的治疗选项，更在肿瘤精准医疗领域树立起一座重要的里程碑。此次获批，无疑将深刻影响胰腺癌治疗的现有格局。对于广大深受胰腺癌困扰的患者群体而言，Rasonque的上市，无疑为他们与病魔的抗争增添了一件有力武器。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","BK4139","RVMD","CANC","IE00BFTCPJ56.SGD","IE0009354923.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","PTH","IE0009355771.USD","IE00BJJMRZ35.SGD","BBH","IDNA","LU0320765992.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662482997","title":"Revolution Medicines的胰腺癌药物 Daraxonrasib已获得美国监管机构的批准，这是首款针对胰腺","url":"https://stock-news.laohu8.com/highlight/detail?id=2662482997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662482997?lang=zh_cn&edition=full","pubTime":"2026-08-26 23:14","pubTimestamp":1787757271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","RVMD","IE00B4R5TH58.HKD","BBH","BK4139","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IDNA","PTH","IE0002141913.USD","LU0109394709.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","CANC","LU0320765992.SGD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114413981","title":"异动解读｜Revolution Medicines盘中下跌5.34%，报200.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114413981","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114413981?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:45","pubTimestamp":1787755511,"startTime":"0","endTime":"0","summary":"8月26日，Revolution Medicines盘中下跌5.34%，报200.13美元/股，成交额8347.87万美元。Revolution Medicines所在的生物科技行业中，个股中，Moderna下跌5.87%，安进下跌0.36%，艾伯维公司下跌1.38%，吉利德科学持平，Natera上涨1.13%。Revolution Medicines是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法以抑制RAS成瘾癌症的前沿靶点，拥有先进的基于结构的药物发现能力。公司过去52周累计涨幅超470%，近期股价处于历史高位区间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123958766","title":"异动解读｜Revolution Medicines盘中上涨5.05%，与百济神州达成RAS抑制剂合作持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1123958766","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123958766?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:35","pubTimestamp":1786988128,"startTime":"0","endTime":"0","summary":"8月18日，Revolution Medicines盘中上涨5.05%，报214.4美元/股，成交额1.42亿美元，延续近期强势上行趋势。消息面上，公司于8月10日宣布与百济神州达成多方面合作协议，涵盖临床联合开发与区域商业化授权。根据协议，百济神州获得公司旗下daraxonrasib、zoldonrasib、elironrasib及RMC-5127四款临床阶段RAS抑制剂在部分亚洲市场的独家开发及商业化权益，并将出资推动一项全球注册性III期研究。其中daraxonrasib在胰腺癌三期试验中中位总生存期达13.2个月，远超化疗的6.7个月，zoldonrasib已获FDA突破性疗法认定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161961","title":"市值超4800亿元的药企股价涨逾4%: 这款“癌王”突破疗法要来中国了","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161961","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658161961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:48","pubTimestamp":1786423687,"startTime":"0","endTime":"0","summary":"8月11日上午，百济神州（ONC.US、06160.HK、688235.SH）A股以及港股股价涨幅超过4%，其中A股市值达到4820亿元。盘面上，公司前一晚与RevolutionMedicines宣布达成临床开发及区域商业化合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837721960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837721960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","LU1548497426.USD","BK4585","IE00BZ199S13.USD","LU2298322129.HKD","LU1978683503.SGD","ON","LU1251922891.USD","IE0002141913.USD","LU0109394709.USD","LU0724618433.USD","IE00BD6J9T35.USD","LU1983260115.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU1770034418.SGD","LU1720051017.SGD","IE00BJJMRZ35.SGD","IDNA","IE00BJT1NW94.SGD","LU0124384867.USD","LU1861219969.SGD","BBH","BK4588","CANC","LU1720051108.HKD","LU0348723411.USD","LU1861214812.USD","IE0009354923.USD","06160","RVMD","LU2357305700.SGD","688235","IE0009355771.USD","LU1861215975.USD","BK1588","BK0239","BK4512","BK4605","KURE","PTH","LU2360107325.USD","LU1854104046.USD","LU1854103824.USD","IE00BFTCPJ56.SGD","BK1583","BK4139","IE00BFMHRM44.USD","LU0588546209.SGD","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965691","title":"港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作 将加快RAS赛道开发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965691?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:42","pubTimestamp":1786412546,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州早盘涨超4%，截至发稿，涨2.72%，报219港元，成交额2.97亿港元。消息面上，8月10日，据百济神州官微消息，公司与Revolution Medicines,Inc.宣布达成一项多方面合作协议。根据协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与Revolution Medicines四款临床阶段RAS抑制剂中任意一款或多款药物的联合治疗方案;同时，双方还达成区域授权协议，百济神州获得Revolution Medicines上述候选药物在部分亚洲市场的独家开发及商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4585","CANC","IE00BJJMRZ35.SGD","LU1303224171.USD","LU2328871848.SGD","06160","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4139","LU0828237510.HKD","LU1969619763.USD","BK0239","LU0889565916.HKD","LU0320765992.SGD","LU0307460666.USD","IE00B2B36J28.USD","BK1161","IE0009354923.USD","LU0228659784.USD","LU1719994722.HKD","RVMD","PTH","BK4526","LU1251922891.USD","ONC","IE00BJT1NW94.SGD","BBH","LU0109394709.USD","LU1770034418.SGD","IE00B4R5TH58.HKD","BK1588","688235","IDNA","KCAI","IE0009355771.USD","BK4588","VXUS","KURE","LU0588546209.SGD","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950149","title":"百济神州与Revolution Medicines达成临床开发及区域商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950149?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:40","pubTimestamp":1786405224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBH","BK4585","LU0109394709.USD","ONC","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4139","IE00B2B36J28.USD","BK4588","IE0009355771.USD","LU0889565916.HKD","CANC","IE00BJT1NW94.SGD","PTH","IDNA","RVMD","IE0009354923.USD","LU0320765992.SGD","BK4526","IE00BFTCPJ56.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950539?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1500","IE00BJJMRZ35.SGD","IDNA","LU0320765992.SGD","BK1588","LU0228659784.USD","BK1574","BK1161","BBH","603087","LU0109394709.USD","BK1515","KURE","LU1969619763.USD","688235","IE00B4R5TH58.HKD","LU1719994722.HKD","IE0009355771.USD","159938","IE00BFTCPJ56.SGD","LU2328871848.SGD","LU0828237510.HKD","RVMD","BK0239","BK4585","BK4526","IE00B2B36J28.USD","LU1770034418.SGD","LU1303224171.USD","ONC","06160","BD","BK4139","IE0002141913.USD","IE0009354923.USD","LU0889565916.HKD","PTH","BK4588","LU0307460666.USD","09939","BK1583","IE00BJT1NW94.SGD","CANC","LU0588546209.SGD","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":-0.0817},{"period":"1month","weight":-0.0863},{"period":"3month","weight":0.0154},{"period":"6month","weight":0.9679},{"period":"1year","weight":2.9853},{"period":"ytd","weight":1.3824}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.063598},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000417},{"month":8,"riseRate":0.714286,"avgChangeRate":0.065126},{"month":9,"riseRate":0.428571,"avgChangeRate":0.032485},{"month":10,"riseRate":0.571429,"avgChangeRate":0.006311},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}